Estudio relacional de las necesidades de soporte según los servicios de lugar de vida utilizados / Relational study of support needs according to life services used

El objetivo del presente estudio es valorar la relación existente entre el grado de atención requerida por los diferentes usuarios y el servicio de lugar de vida que están utilizando. Para ello se ha realizado un estudio con 388 personas. Las variables estudiadas incluyen el diagnóstico, la edad, el sexo, la situación económica y la Escala ENAR-CPB. El porcentaje de hombres es superior al de mujeres. Los jóvenes son tratados principalmente en los pisos supervisados. Mayoritariamente se atienden esquizofrenias paranoides, sobre todo en las residencias. Las depresiones mayores están sobre todo en el propio domicilio y los trastornos límites de la personalidad son atendidos principalmente en pisos supervisados. Las personas que viven en una residencia son por lo general más dependientes que las que viven en pisos supervisados o en su propio domicilio. Es importante ajustar lo más posible el recurso de lugar de vida a las capacidades y necesidades reales de la persona, pero la situación económica personal marca la diferencia entre el hecho de ir a vivir a un piso supervisado o mantenerse en el propio domicilio. (AU)

This study was conducted with the aim of evaluating the relationship existing between the degree of care required by users of different mental health services and the services provided in the place they are using. The study was performed on a 388-person sample. The variables studied included diagnosis, age, sex, economic circumstances, and the ENAR-CPB scale. In all resources, the percentage of men with support outnumbered that of women. On the other hand, young people were found to mostly be living in supportive housing. The majority in all resources suffered from paranoid schizophrenia, especially in long-term care facilities. Clients with severe depression generally lived in their own homes, while those with borderline personality disorder were mainly attended in supportive housing. The residences clients were more dependent than those living whether in supportive housing or in their own home. It is important to relate the housing resource to a person's real capabilities and needs as much as possible; however, it is economic capacity what determines whether a person lives in a supportive housing unit or in their own home. (AU)

Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™).

BACKGROUND: Additional antibiotic options are needed to treat bone and joint infections caused by penicillin-resistant Gram-positive pathogens. OBJECTIVE: This subanalysis of the Telavancin Observational Use Registry (TOUR™) aimed to record real-world telavancin usage patterns in patients with bone and joint infections treated with telavancin. METHODS: TOUR was a multicenter observational-use registry study conducted at 45 US sites between January 2015 and March 2017. Patient characteristics, infection type, infecting pathogen(s), previous treatment, telavancin dosing and duration, clinical response, and adverse event data were collected by retrospective medical chart reviews. As such, inclusion/exclusion criteria were limited, and any patient receiving at least one dose of telavancin at the discretion of the treating physician was eligible. Patients were assessed as either positive clinical response, failed treatment, or indeterminate outcome. RESULTS: Of the 1063 patients enrolled in TOUR, 27.4% (291/1063) were patients with bone and joint infections including osteomyelitis (with or without prosthetic material), acute septic arthritis, and prosthetic joint infections. Most of these patients had osteomyelitis without prosthetic material (191/291; 66.0%). Among patients assessed at the end of treatment, 211/268 (78.7%) achieved a positive clinical response, 26/268 (9.7%) failed treatment, and 31/268 (11.6%) had an indeterminate outcome. The most frequent pathogen was methicillin-resistant Staphylococcus aureus (110/291; 37.8%). The median (interquartile range [IQR as Q1, Q3]) telavancin dose was 750.0 mg (IQR, 750, 750 mg) or 8.2 mg/kg (IQR, 6.8, 9.7 mg/kg) administered for a median of 26 days (IQR, 12, 42 days). These assessments were recorded in the registry ≥ 30 days after the last dose of telavancin was administered. CONCLUSIONS: Real-world data from the TOUR study show that clinicians are using once-daily telavancin with positive clinical outcomes for the treatment of bone and joint infections caused by Gram-positive pathogens. CLINICAL TRIAL REGISTRATION: This trial was registered with ClinicalTrials.gov (NCT02288234) on 11 November, 2014.

Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Real-World Results from the Telavancin Observational Use Registry (TOUR™).

BACKGROUND: Bacteremia and endocarditis caused by Staphylococcus aureus (S. aureus), particularly methicillin-resistant S. aureus (MRSA), are challenging to treat and are associated with high morbidity and mortality. Telavancin is a lipoglycopeptide antibacterial active against susceptible Gram-positive pathogens, including MRSA. OBJECTIVE: This registry study assessed the real-world use and clinical outcomes of telavancin in patients with bacteremia or endocarditis enrolled in the Telavancin Observation Use Registry (TOUR™). METHODS: The subset of patients enrolled in TOUR who were diagnosed with endocarditis and/or bacteremia with a known or unknown primary source (N = 151) were analyzed. Data including demographics, infection type, baseline pathogens, prior or concomitant antimicrobial therapy, dosing regimen, clinical response, treatment-emergent adverse events (TEAEs) of interest, and mortality were collected by retrospective medical chart review. RESULTS: Telavancin was primarily used as a second-line or greater therapy (n = 132, 87.4%). MRSA was present in 87 (57.6%) patients. Median telavancin dose was 740.6 mg (interquartile range (IQR) 206.0 mg) and median duration of therapy was 9.0 days (IQR 24.0 days). Of the 132/151 (87.4%) patients with an available assessment at the end of telavancin therapy, a positive clinical response was achieved in 98/132 (74.2%), while 14/132 (10.6%) failed therapy and 20/132 (15.2%) had an indeterminant outcome. TEAEs occurred in 24 (15.9%) patients. The most frequent TEAE was renal failure (n = 12, 7.9%); seven of these patients were receiving concomitant nephrotoxic medications. There was no change in creatinine clearance for 67/89 (75.3%) patients with values recorded at the beginning and the end of telavancin therapy. CONCLUSIONS: In real-world clinical practice, overall positive clinical outcomes are observed in patients with bacteremia or endocarditis treated with telavancin, including in those patients infected with MRSA or another S. aureus pathogen. Telavancin may be an alternative treatment option for these patients. TRIAL REGISTRATION: This trial was registered with clinicaltrials.gov (NCT02288234) on 11 November 2014.

Niveles de calprotectina fecal en pacientes con anticuerpos anti-transglutaminasa positivos y pacientes con dieta libre de gluten / Fecal calprotectin levels in patients with positive anti-transglutaminase antibodies and patients on a gluten free diet / Niveis de calprotectina fecal em pacientes com anticorpos anti-transglutaminase positivos e pacientes com dieta livre de gluten

La calprotectina fecal se ha afianzado en los últimos años como un marcador útil de las patologías gastrointestinales. El objetivo de este estudio fue determinar los niveles de calprotectina fecal (CPF), interleuquina-6 (IL-6) y proteína C reactiva (PCR) en tres grupos de pacientes: con diagnóstico de novo de enfermedad celíaca, con diagnóstico previo y dieta libre de gluten (DLG) y un grupo control. Se colectaron muestras de 79 pacientes entre 18 y 65 años. A todos se les determinó CPF, IL-6 y PCR como marcadores de inflamación y anticuerpos anti-transglutaminasa IgA y anti-gliadinas desaminadas IgA e IgG como marcadores serológicos. Se encontraron valores significativamente incrementados de PCR en el grupo de novo (124,06 μg/g) comparados con el grupo con DLG (23,61 μg/g) y el grupo control (16,91 μg/g) respectivamente. No se encontraron diferencias entre el grupo con DLG y el negativo (control). Idéntico comportamiento se observó para IL-6 con valores en el grupo de novo de 2,39 μg/dL, 1,74 μg/dL en el grupo con DLG y 1,41 μg/dL en el control negativo. No se encontraron diferencias significativas en el análisis de resultados de PCR. Se encontró una excelente sensibilidad (98,0%) y especificidad (96,6%) en la capacidad de la CPF para diferenciar valores de anti-transglutaminasa IgA superiores o inferiores al punto de corte cuando se estimó el índice de Youden. Se podría considerar a la CPF como un posible marcador sensible para indicar inflamación intestinal de manera no invasiva en la enfermedad celíaca.

The determination of fecal calprotectin has been strengthened in recent years as a useful marker of gastrointestinal pathologies. The objective of this study was to determine the levels of fecal calprotectin (FCP), interleukin-6 (IL-6) and C-reactive protein (CRP) in three groups of patients: with de novo diagnosis of celiac disease, with previous diagnosis and gluten-free diet (GFD) and a control group. Samples were collected from 79 patients between 18 and 65 years old. In all cases, FCP, IL-6 and RCP were determined as markers of inflammation and anti-transglutaminase IgA and deaminated anti-gliadin IgA and IgG antibodies as serological markers. Significantly more increased FCP values were found in the de novo group (124.06 μg/g) than in the group with DLG (23.61 μg/g) and the control group (16.91 μg/g). No differences were found between the group with GFD and the negative. The same trend was observed for IL-6 with values in the de novo group of 2.39 μg/dL, 1.74 μg/dL in the group with gluten free diet and 1.41 μg/dL in the negative control. No significant differences were found in the analysis of RCP results. Excellent sensitivity (98.0%) and specificity (96.6%) were found in the capability of the FCP to differentiate anti-transglutaminase IgA values higher or lower than the cut-off point when the Youden index was estimated. The FCP could be considered as a possible sensitive marker to indicate intestinal inflammation in a non-invasive manner in celiac disease.

A calprotectina fecal se consolidou nos ultimos anos como um marcador util das patologias gastrointestinais. O objetivo deste estudo foi determinar os niveis de calprotectina fecal (CPF), interleucina-6 (IL-6) e proteina C-reativa (PCR) em tres grupos de pacientes; com diagnostico de novo de doenca celiaca, com diagnostico previo e dieta livre de gluten (DLG) e um grupo controle. Foram coletadas amostras de 79 pacientes entre 18 e 65 anos. Em todos os casos CPF, IL-6 e PCR foram determinadas como marcadores de inflamacao e anticorpos anti-transglutaminase IgA e anti-gliadinas desaminadas IgA e IgG como marcadores sorologicos. Valores significantemente mais altos de PCR foram detectados no grupo de novo (124,06 μg/g) comparados com o grupo com DLG (23,61 μg/g) e o grupo controle (16,91 μg/g) respectivamente. Nao foram encontradas diferencas entre o grupo com DLG e o negativo (controle). O mesmo comportamento foi observado para IL-6 com valores no grupo de novo de 2,39 μg/dL, 1,74 μg/dL no grupo com DLG e 1,41 μg/dL no controle negativo. Na analise de resultados da PCR nao foram encontradas diferencas significativas. Foram detectadas uma sensibilidade excelente (98,0%) e especificidade (96,6%) na habilidade da CPF para diferenciar valores de anti-transglutaminase IgA superiores ou inferiores ao ponto de corte quando o indice de Youden foi estimado. Poderia ser considerada a CPF como um possivel marcador sensivel para identificar inflamacao intestinal de forma nao invasiva na doenca celiaca.

Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™).

BACKGROUND: Telavancin-a lipoglycopeptide antibacterial agent active against Gram-positive pathogens including methicillin-sensitive and -resistant Staphylococcus aureus (MRSA)-is approved in the USA for once-daily intravenous use. This registry study captured patient characteristics, prescribing patterns, and treatment outcomes associated with telavancin use in real-world clinical practice. OBJECTIVE: This prospective, multicenter, observational study will characterize current real-world practice patterns for the use of telavancin in the USA by describing demographic and clinical conditions, examining the process of care and rationale for use, and describing the clinical effectiveness and selected safety outcomes among patients treated with telavancin. METHODS: The Telavancin Observational Use Registry (TOUR™) is an observational multicenter registry study. Clinical data-including patient demographics, pathogens, telavancin dosing and treatment duration, and adverse events-along with investigators' assessments of outcome, were collected through retrospective medical chart review. RESULTS: Data from 1063 patients were collected from 45 US sites. Of these patients, 29.4% were ≥ 65 years of age [mean age ± standard deviation, 55.2 ± 15.4 years; median age (interquartile range), 57.0 (46.0-66.0)], 53.4% were male, and 83.4% were White. The primary infections in these patients included complicated skin and skin-structure infection (48.7%), bone and joint infections (27.4%), bacteremia and endocarditis (14.2%), and lower respiratory tract infections (8.5%). The predominant pathogen identified was MRSA (37.7%). The mean telavancin dose and duration of treatment were 741.7 ± 194.3 mg and 17 ± 17 days, respectively. Of the 964 (90.7%) patients for whom an end-of-treatment assessment was available, 77.7% had a positive clinical response, 10.1% failed treatment, and 12.2% had indeterminate outcomes. CONCLUSIONS: Real-world data collected from the TOUR study show once-daily telavancin is being used for the treatment of a variety of Gram-positive infections with generally positive clinical outcomes.

Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials.

INTRODUCTION: The efficacy and safety of telavancin versus vancomycin in microbiologically evaluable patients with hospital-acquired or ventilator-associated pneumonia (HAP/VAP) caused by Staphylococcus aureus with vancomycin minimum inhibitory concentration (MIC) ≥ 1.0 µg/mL was analyzed using data derived from previously reported Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia (ATTAIN) trials. METHODS: This post hoc subgroup analysis of two randomized, double-blind, comparator-controlled, parallel-group phase 3 trials conducted at 274 sites in 38 countries included 194 microbiologically evaluable patients with HAP/VAP caused by monomicrobial S. aureus with vancomycin MIC ≥ 1.0 µg/mL. Patients received intravenous telavancin (10 mg/kg every 24 h) or intravenous vancomycin (1 g every 12 h with site-specific modifications) for 7-21 days. Efficacy was assessed by clinical cure, defined as improvement or non-progression of radiographic findings at end of treatment and resolution of pneumonia signs and symptoms at follow-up/test-of-cure visits, and survival 28 days post-randomization. Safety was assessed from categorical shifts in creatinine clearance during therapy and adverse events (AEs). RESULTS: Clinical cure rates were numerically greater following telavancin versus vancomycin treatment overall (85.4% vs. 74.3%; treatment difference [95% confidence interval (CI)], 11.1% [- 0.002%, 22.2%]) and in patients aged ≥ 65 years (81.6% vs. 66.2%; treatment difference [95% CI], 15.5% [- 0.9%, 30.2%]) patients with VAP (92.3% vs. 47.6%; treatment difference [95% CI], 44.7% [18.1%, 64.9%]), and patients with baseline Acute Physiology And Chronic Health Evaluation II score ≥ 20 (71.4% vs. 55.6%; treatment difference [95% CI], 15.9% [- 11.7%, 40.5%]). Renal function declined in 7 (7.9%) patients receiving telavancin and 6 (5.7%) patients receiving vancomycin. Survival proportion was numerically higher (85.2% vs. 80.2%; treatment difference [95% CI], 5.0% [- 5.8%, 15.8%]) and AEs were comparable in patients treated with telavancin versus vancomycin. CONCLUSION: Telavancin is an alternative to vancomycin for HAP/VAP caused by S. aureus with vancomycin MIC ≥ 1 µg/mL. FUNDING: Theravance Biopharma R&D, Inc., South San Francisco, CA, USA.

Considerations for Clinical Trials of Staphylococcus aureus Bloodstream Infection in Adults.

Clinical trials for Staphylococcus aureus bloodstream infections (SAB) are broadly grouped into 2 categories: registrational trials intended to support regulatory approval of antibiotics for the treatment of SAB and strategy trials intended to inform clinicians on the best treatment options for SAB among existing antibiotics. Both types of SAB trials are urgently needed but have been limited by cost, complexity, and regulatory uncertainty. Here, we review key SAB trial design considerations for investigators, sponsors, and regulators.

Descriptive study of evolution experienced by users of mental health residence, after 10 years of operation.

INTRODUCTION: The transformation of the social-health benefits system must demonstrate efficiency. The objective of the current work is to evaluate the evolution of those living in a residence during the first 10 years of its operation. METHOD: Of the 205 patients used in the assessment, 93 were admitted. The evolutionary study was done with the 62 patients that were cared for between 2002-2012. The variables studied include the ENAR-CPB Scale, days hospitalized, community activities, a satisfaction survey and QOL. RESULTS: After the assessment process only 45% of those proposed for admission were actually admitted. Resident rotation is 3.4% annually. Many leave the program after being referred to a long-term psychiatric hospital; 14.5% leave the residence in order to have a more autonomous life. After living 2 years in the residence there is a general improvement in the majority of residents, which is maintained after 5 years as well. This improvement is maintained even after 10 years, however a general loss of capacities is experienced. CONCLUSIONS: Living in a Residence favors improvement in the quality of life, both subjectively as well as objectively. Institutional treatment consists of working with the patients in a way that treats them as individuals, so they can go about their lives and perform their tasks with creativity. In order for this to be possible, an individualized and flexible model is required.

Estudio descriptivo de la evolución experimentada por los usuarios de una residencia de salud mental, tras 10 años de funcionamiento / Descriptive study of evolution experienced by users of mental health residence, after 10 years of operation

Introducción. La transformación del sistema de prestaciones socio-sanitarias tiene que demostrar eficiencia. El objetivo de este trabajo es evaluar la evolución de los residentes atendidos en una residencia durante sus primeros 10 años de funcionamiento. Método. De 205 personas que optaron por plaza de residencia, 93 fueron admitidos. El estudio evolutivo se realiza con 62 pacientes atendidos entre 2002-2012. Las variables estudiadas incluyen la Escala ENAR-CPB, días de hospitalización, actividades comunitarias, encuesta de satisfacción y QOL. Resultados. Tras el proceso de valoración sólo ingresan un 45% de los usuarios propuestos. La rotación de residentes es del 3,4% anual, siendo la derivación a un recurso de hospitalización psiquiátrica de larga estancia la mayor causa de baja del programa. El 14,5%, en cambio, deja la residencia por un proyecto de vida más autónomo. A los 2 años de ingreso la mejoría es mayoritaria, a los 5 se mantiene y a los 10 se produce una pérdida general de capacidades, pero manteniéndose una mejoría respecto al momento del ingreso. Conclusiones. Vivir en una residencia favorece la mejoría en la calidad de vida de los residentes; tanto subjetiva como objetivamente. El tratamiento institucional consiste en ir trabajando con los usuarios y negociar desde su singularidad el modo de que no se sometan y puedan ejecutar creativamente su tarea. Para ello es necesario un modelo de intervención individualizado y flexible (AU)

Introduction. The transformation of the social-health benefits system must demonstrate efficiency. The objective of the current work is to evaluate the evolution of those living in a residence during the first 10 years of its operation. Method. Of the 205 patients used in the assessment, 93 were admitted. The evolutionary study was done with the 62 patients that were cared for between 2002-2012. The variables studied include the ENAR-CPB Scale, days hospitalized, community activities, a satisfaction survey and QOL. Results. After the assessment process only 45% of those proposed for admission were actually admitted. Resident rotation is 3.4% annually. Many leave the program after being referred to a long-term psychiatric hospital; 14.5% leave the residence in order to have a more autonomous life. After living 2 years in the residence there is a general improvement in the majority of residents, which is maintained after 5 years as well. This improvement is maintained even after 10 years, however a general loss of capacities is experienced. Conclusions.Living in a Residence favors improvement in the quality of life, both subjectively as well as objectively. Institutional treatment consists of working with the patients in a way that treats them as individuals, so they can go about their lives and perform their tasks with creativity. In order for this to be possible, an individualized and flexible model is required (AU)

Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies.

INTRODUCTION: Concurrent Staphylococcus aureus bacteremia (SAB) worsens outcomes and increases mortality in patients with complicated skin and skin structure infections (cSSSI), hospital-acquired bacterial pneumonia, and ventilator-associated bacterial pneumonia (HABP/VABP). These challenges highlight the need for alternative treatments. Telavancin (TLV), a bactericidal lipoglycopeptide with high in vitro potency, effectively treats patients with cSSSI and HABP/VABP caused by Gram-positive pathogens, particularly S. aureus. METHODS: This retrospective analysis evaluated patients from the Assessment of Telavancin in Complicated Skin and Skin Structure Infections and Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia studies with baseline, concurrent SAB. Differences in the clinical cure rates at test-of-cure and safety outcomes were compared for TLV vs vancomycin (VAN) treatment groups. RESULTS: A total of 105 patients, 32 cSSSI and 73 HABP/VABP, had baseline, concurrent SAB. The clinical cure rates for all-treated SAB patients in the cSSSI (TLV 57.1% and VAN 54.5%) and HABP/VABP (TLV 54.3% and VAN 47.2%) groups were comparable. For both types of infections, the safety profile of TLV and VAN showed similar incidences of adverse events (AEs), serious AEs, or AEs leading to discontinuation. One VAN-treated patient died in the cSSSI group, and there were 13 deaths in each treatment arm of the HABP/VABP group. CONCLUSION: This retrospective analysis demonstrated that TLV is clinically comparable in both efficacy and safety to VAN, and, therefore, may be an appropriate therapeutic option for the treatment of patients with HABP/VABP or cSSSI and concurrent SAB. Given the limited sample size in this subgroup, the interpretation of these results is limited. FUNDING: Theravance Biopharma Antibiotics, Inc.

Safety and Tolerability of Doripenem in Hospitalized Children With Complicated Intra-Abdominal Infection, Complicated Urinary Tract Infections and Pneumonia.

Three multicenter, randomized, controlled studies evaluated doripenem in children 3 months to <18 years of age, with complicated intra-abdominal or urinary tract infections and bacterial pneumonia.In the 66 patients treated with doripenem before early termination of the studies for nonsafety reasons, doripenem was safe and generally well tolerated. Low enrollment limited ability to assess benefits and risks of doripenem in children.

Open-Label Study To Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants Less than 12 Weeks in Chronological Age.

Doripenem, a parenteral carbapenem with broad-spectrum activity against aerobic Gram-negative and Gram-positive and anaerobic pathogens, is currently approved for use in adults in the United States and European Union. Single-dose doripenem pharmacokinetics in 52 infants <12 weeks in chronological age were investigated in this phase 1 study. Hospitalized, medically stable infants <12 weeks in chronological age were stratified into 6 groups based on chronological and gestational age designed to reflect increasing renal maturation and decreasing volume of distribution (Vz) for ß-lactam antimicrobials during the first 3 months of life. Subjects received single-dose doripenem (5 mg/kg of body weight for <8 weeks and 8 mg/kg for ≥8 weeks in chronological age) administered intravenously over 1 h. Plasma samples were obtained immediately before the end of the infusion and 1.5, 3, and 7 h after the start of the infusion. Urine was obtained by indwelling catheter during the 8 h following infusion. Doripenem showed linear pharmacokinetics across the 6 age groups. Neonates (<4 weeks in chronological age) had increased mean exposure (area under the plasma concentration-time curve from time zero to infinite time [AUC∞], 45.7 versus 32.4 µg · h/ml), longer elimination half-life (2.98 versus 1.79 h), and lower clearance (2.03 versus 3.03 ml/min/kg) compared with infants >4 weeks. Mean Vz was highest in subjects with the earliest gestational age (<32 weeks): 0.564 liter/kg for neonates and 0.548 liter/kg for infants. Single-dose pharmacokinetics of doripenem administered as a 1-hour infusion in term and preterm infants <12 weeks in chronological age were similar to what has been observed in neonates and very young infants with other carbapenems. Single-dose doripenem was generally safe and well tolerated. (This study has been registered with ClinicalTrials.gov under registration no. NCT01381848 and with EudraCT under registration no. 2009-014387-20.).

Las residencias para personas con Trastorno Mental Grave como un recurso Terapéutico-Rehabilitador / The residences for persons with Several Mental Disorder as a Therapeutic-Rehabilitation resource

Introducción: El desarrollo de lugares de vida para personas con TMG está significando un factor importante en la consolidación de la atención comunitaria en Salud Mental. Las residencias deben considerarse como un lugar de rehabilitación psicosocial, al modificar una situación psicosocial disfuncional que influye negativamente en la calidad de vida y en la integración social del paciente. En esta línea se plantea el presente estudio con El objetivo: de evaluar la evolución de los residentes ingresados en las residencias Roger de Llúria, Tres Pins y Begur, (gestionadas por la Fundación de Salud Mental CPB), en sus dos primeros años de ingreso y poder definir los aspectos de mejoría en los usuarios. Material y Método: La muestra inicial es de 88 personas (usuarios ingresados durante los años. (2009- 2011). Se comparan las variaciones en el tiempo de ingreso psiquiátrico, la utilización de recursos de rehabilitación comunitaria, la estabilidad clínica, la realización de Actividades de la Vida Diaria (AVD) y la calidad de vida (desarrollo personal y social); tomando como valorares la información recogida durante el año anterior a su incorporación a la residencia y a los dos años de vinculación. Resultados y Conclusiones: Se puede afirmar que la estancia en las residencies favorece la estabilidad clínica del usuario, reduciendo el número de ingresos y su tiempo de estancia. El residente mejora en el funcionamiento general en las AVD, hábitos de salud y relaciones personales, recuperando su estatus de ciudadano, más activo y autónomo. La mejora en el ajuste social y ocupacional se refleja en el aumento de recursos de rehabilitación utilizados y la mayor participación en la vida comunitaria (tanto dentro como fuera de la residencia) (AU)

Introduction: The development of housing places for people with SMD is becoming an important factor in the consolidation of community care in mental health. Residences should be considered as a psychosocial rehabilitation place, modifying a dysfunctional psychosocial situation that negatively affects quality of life and social integration of the patient. In this line arises the present study in order to assess the evolution of the residents admitted to Roger de Llúria, Begur and Tres Pins residences (managed by the Mental Health Foundation CPB) in its first two years of admission to the mental health centre and being able to define improvement aspects on users. Material and Method: From an initial sample of 88 residents (admitted during the years 2009-2011). Comparing the variations during the required time of psychiatric admission, use of community rehabilitation resources, clinical stability, performing ADLs and quality of life (social and personal), taking as values the collected information during the year preceding their incorporation into the residence and the two years of relationship. Results: We could affirm that staying at residences favours users’ clinical stability, reducing the number of admissions and their length of stay. The resident improves in ADLs functioning, health habits and personal relationships, regaining his citizen ship status, more active and self-sufficient. The improvement in social and occupational residents adjustment is reflected in the increasing of rehabilitation resources used and a greater participation in community life (both inside and outside the residence) (AU)